Are you on the path to launching a clinical trial within the next 12-18 months and eager to connect with a network of experts who can help?

The Cicada HealthTech Hub Open House offers you the chance to meet with seasoned experts who excel in leading and facilitating clinical trials. Get your crucial questions answered, acquire essential insights, and develop a solid action plan for launching your clinical trial.

Join us at the Cicada HealthTech Hub Open House—an invaluable opportunity to engage in open discussions with SME founders and industry specialists experienced in running and setting up clinical trials.

The discussion will include:

- Investigator-Initiated-Study (IIS) or Phase I

- How to maximise recruitment and retention

- How to choose a CRO partners (costs, experience, location, expertise)

- Data management (privacy, analysis, presentation)

Whether you're close to initiating your trial or still laying the groundwork, this event is designed to clarify the clinical trial process and address your immediate queries, you will also have the option to take a guided tour of our Healthtech hub facilities.

Meet the Panel:

In addition to the insightful panel discussion, take the opportunity to explore our facilities. Get a glimpse of where tomorrow's breakthroughs in health tech are being forged.

Event Agenda:

4:30 - 5:00 pm Registration, Networking, and Tour of Health Tech Hub Incubator Space
5:00 - 5:45 pm Panel Discussion & Q&A
5:45 - 6:30 pm Networking

The Cicada HealthTech Hub will be a home to early stage health companies, a space for collaboration and commercialisation activation, and a landing pad for industry seeking solutions to their research and business challenges.

Find out more about the Cicada Health Tech Hub

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.